Several biologic therapies have been used in patients with refractory OLP, including anti-CD2, anti-TNF-alpha, anti-IL2, anti-IL17, anti-IL12/23, and anti-IL23 drugs (Table 2) (15, 27). The gene discussed is TNF; the disease is oral lichen planus.